Literature DB >> 11311063

Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.

S A Gamage1, J A Spicer, G J Finlay, A J Stewart, P Charlton, B C Baguley, W A Denny.   

Abstract

Bis(9-methylphenazine-1-carboxamides) joined by a variety of dicationic (CH(2))(n)()NR(CH(2))(m)NR(CH(2))(n) linkers of varying length (carboxamide N-N distances from 11.0 to 18.4 A) and rigidity were prepared by reaction of 9-methylphenazine-1-carboxylic acid imidazolide with the appropriate polyamines. The compounds were evaluated for growth inhibitory properties in P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia with low levels of topoisomerase II (topo II). The compounds all had IC(50) ratios of <1 in the resistant Jurkat lines, consistent with topo II inhibition not being the primary mechanism of action. Analogues joined by an (CH(2))(2)NR(CH(2))(2)NR(CH(2))(2) linker were extremely potent cytotoxins, with selectivity toward the human cell lines, but absolute potencies declined sharply from R = H through R = Me to R = Pr and Bu. In contrast, (CH(2))(2)NR(CH(2))(3)NR(CH(2))(2) compounds showed reverse effects, with the R = Me analogue being more potent than the R = H one as well as being the most potent in the series [IC(50) in JL(C) cells 0.08 nM; superior to that for the clinical bis(naphthalimide) LU 79553]. Overall, the IC(50)s of analogues with linker chains (CH(2))(n)NH(CH(2))(m)NH(CH(2))(n) were inversely proportional to linker length. Constraining the rigidity of the linker chain by incorporating a piperazine ring did not decrease potency significantly. A representative compound bound tightly to DNA with high selectivity for GC sites, compatible with recent work suggesting that compounds of this type place their side chains in the major groove, making specific contacts with guanine bases. Representative compounds were susceptible to transport mediated resistance, being much less effective in cells that overexpressed P-glycoprotein. Overall the results suggest these compounds have a similar mode of action, mediated primarily by poisoning of topo I (possibly with some involvement of topo II). The bis(9-methylphenazine-1-carboxamides) show very high in vitro growth inhibitory potencies compared to their monomeric analogues. Two compounds showed in vivo activity in murine colon 38 syngeneic and HT29 human colon tumor xenograft models using intraperitoneal dosing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311063     DOI: 10.1021/jm0003283

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.

Authors:  Clement Lin; Danzhou Yang
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

2.  Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator.

Authors:  Clement Lin; Raveendra I Mathad; Zhenjiang Zhang; Neil Sidell; Danzhou Yang
Journal:  Nucleic Acids Res       Date:  2014-04-07       Impact factor: 16.971

Review 3.  An overview of recent advances in duplex DNA recognition by small molecules.

Authors:  Sayantan Bhaduri; Nihar Ranjan; Dev P Arya
Journal:  Beilstein J Org Chem       Date:  2018-05-16       Impact factor: 2.883

4.  Synthesis, Biological Activity and Preliminary in Silico ADMET Screening of Polyamine Conjugates with Bicyclic Systems.

Authors:  Marta Szumilak; Malgorzata Galdyszynska; Kamila Dominska; Irena I Bak-Sypien; Anna Merecz-Sadowska; Andrzej Stanczak; Boleslaw T Karwowski; Agnieszka W Piastowska-Ciesielska
Journal:  Molecules       Date:  2017-05-12       Impact factor: 4.411

5.  Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

Authors:  S M Harris; P Mistry; C Freathy; J L Brown; P A Charlton
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

6.  Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

Authors:  Kathryn A Whitehead; J Robert Dorkin; Arturo J Vegas; Philip H Chang; Omid Veiseh; Jonathan Matthews; Owen S Fenton; Yunlong Zhang; Karsten T Olejnik; Volkan Yesilyurt; Delai Chen; Scott Barros; Boris Klebanov; Tatiana Novobrantseva; Robert Langer; Daniel G Anderson
Journal:  Nat Commun       Date:  2014-06-27       Impact factor: 14.919

Review 7.  Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.

Authors:  Adam J Buric; Jonathan Dickerhoff; Danzhou Yang
Journal:  Molecules       Date:  2021-07-07       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.